[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"transverse-myelitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:transverse-myelitis":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,47,77,100,120],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100652668","pattern-of-afp-in-chhidren-admitted-at-sohag-university-hospital-100652668",false,"NCT07775066","Pattern of AFP in Chhidren Admitted at Sohag University Hospital","Spectrum of Acute Flaccid Paralysis in Children Admitted at Sohag University Hospital","AFP-SUH","Inclusion Criteria:\n\n* All patients admitted to pediatric emergency and intensive care units with claim or suspected to have acute flaccid paralysis aged from 1 month Up to 16 years old\n\nExclusion Criteria:\n\n* Children with flaccid paralysis due to causes other than neurogenic causes. No clear history or clinical picture of definite neurological cause. incomplete clinical data.","ALL","1 Month","16 Years",{"count":21,"type":22},30,"ESTIMATED","OBSERVATIONAL","This study is observational study aims to study the Clinical profile, Possible risk factors and Outcome of Acute flaccid paralysis in children at Sohag University Hospital.\n\nOur study will include all children admitted to pediatric emergency and intensive care units with claim or suspicion to have acute falccid paralysis",[26,27,28,29],"Acute Flaccid Paralysis","AFP","Gullian Barre Syndrome","Transverse Myelitis",[31,32,33,28],"acute flaccid paralysis","afp","Transverse myelitis","NOT_YET_RECRUITING","2026-08-15",{"date":37,"type":38},"2026-08-20","ACTUAL",{"date":40,"type":22},"2026-08-01",{"date":42,"type":22},"2027-09-01",{"name":44,"class":45},"Mohamed Aboelhamd Ali","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":62,"conditions":63,"keywords":64,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":46},"100353852","phase-1-study-to-investigate-the-safety-of-the-transplantation-of-human-glial-restricted-progenitor-cells-into-subjects-with-transverse-myelitis-100353852","NCT03887273","Study to Investigate the Safety of the Transplantation of Human Glial Restricted Progenitor Cells Into Subjects With Transverse Myelitis","A Phase 1\u002F2a Open-Label Study to Investigate the Safety of the Transplantation (by Injection) of Human Glial Restricted Progenitor Cells (hGRPs; Q-Cells®) Into Subjects With Transverse Myelitis (TM)","Inclusion Criteria:\n\n1. Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to collect and use protected health information (PHI) in accordance with national and local subject privacy regulations.\n2. Live within reasonable travel distance to center or have reliable mechanism to travel to the center.\n3. Have a caregiver willing\u002Fable to assist in the transportation and care required by study participation.\n4. Subject is 18 - 70 years of age (inclusive) on day of Screening Visit.\n5. Subject is diagnosed with idiopathic TM within the past 120 months in accord with the Transverse Myelitis Consortium Working Group (2002).\n6. Subject has an MRI with a single focus of T2 hyperintensity with its most rostral extent at or below C8 myotome\u002Fdermatome level.\n7. Subject has negative NMO IgG (anti-AQP4) test at two separate time points, separated by at least 6 months.\n8. Subject has brain MRI not consistent with multiple sclerosis or other autoimmune or demyelinating disease.\n9. Subject is more than 12 months from TM onset.\n10. Subject has ASIA A, B or C categorization, and is unable to ambulate (Cohort A) or unable to ambulate 100 feet without significant bilateral support. (Cohort B).\n11. Subject's neurological deficits related to TM have been stable for at least 3 months.\n12. Subject is medically able to undergo the study procedures and physically able to adhere to the visit schedule at the time of study entry.\n13. For women of child bearing capacity, negative pregnancy test during the Screening Period and at the Pre-Operative Visit.\n14. Males and females will agree to practice effective birth control during study participation and up to one year after.\n15. Current, up to date, COVID vaccination.\n16. Current, up to date, varicella zoster vaccination.\n17. Current, seasonally up to date, influenza vaccination.\n\nExclusion Criteria:\n\n1. Subject with causes of weakness, sensory loss and\u002For autonomic dysfunction other than TM have not been practically excluded.\n2. Subject with significant cognitive impairment, clinical dementia, or major psychiatric illness including psychosis, bipolar disease, major depression, as determined by the DSM-V that will interfere with participation in the trial.\n3. Subject with a diagnosis of a neurodegenerative disease (e.g., ALS, Parkinson's disease, Alzheimer's disease).\n4. Subject suffering with medical conditions that impair nerve or muscle function (e.g., notable peripheral neuropathy, metabolic muscle disease) or any disease or condition that would impair the subject's neuromuscular function or impair the adequate assessment of the subject's function (e.g., severe osteoarthritis).\n5. Subject with a clinically significant history of unstable cardiac, pulmonary, renal, hepatic, endocrine, hematologic, or active malignancy or infectious disease or other medically significant illness that may render them at an unacceptable risk for surgery or that may cause them to be unable to complete the scheduled duration of the trial.\n6. History of spine surgery or anatomic variation incompatible with route of administration (as determined by neurosurgeon).\n7. Severe spinal stenosis or cord compression causing myelopathy.\n8. Abnormal flow voids on the surface of the spinal cord suggestive of arteriovenous malformation (AVM) or evidence of a vascular cause of a myelopathy (e.g., infarct of spinal artery).\n9. Any evidence of CNS malignancy or clinically significant CNS lesions as defined by imaging studies of the CNS (MRI of brain and spinal cord).\n10. Uncontrolled hypertension (Systolic BP\\>180mmHg and\u002For Diastolic BP \\>110mmHg).\n11. Any poorly controlled medical conditions that, in the opinion of the site investigator and\u002For surgeon, increase risk of surgery to a medically unacceptable degree.\n12. Subjects who cannot undergo MRI examination because of any contraindication to the procedure, including the presence of a pacemaker, an implanted defibrillator or certain other implanted electronic or metallic devices, or who have been or might have been exposed to metal fragments, or any reason the subject cannot undergo an MRI routinely for the duration of the trial.\n13. Subject with clinically significant abnormal clinical laboratory values, as determined by the Investigator at the screening visit (Visit 1).\n14. Subject who is immune compromised (by therapeutic agent or disease) or who has a condition contraindicated to treatment with immunosuppression agents (e.g., tuberculosis, latent infection) as determined by history or testing. Any subject with an ongoing infection until it has been adequately treated and it is deemed to be resolved.\n15. Subject with aspartate aminotransferase (AST) or alanine aminotransferase (ALT) value \\>3.0 times the upper limit of normal at the screening visit (Visit 1).\n16. Subject with diabetes or HgbA1c \\> 6.5.\n17. Subject with a history of alcohol or drug abuse or dependence within 1 year of screening visit (Visit 1), per DSM-V criteria.\n18. Subject unlikely to comply with study requirements, as determined by Investigator.\n19. Subject who has been exposed to any other experimental agent (off-label use or investigational) within 60 days of screening visit (Visit 1). Biologic agents may need additional time for washout and will be evaluated by the Sponsor on a case-by-case basis.\n20. Subject with pre-existing severe or high titer anti-human leukocyte antigen (HLA) class I or class II antibodies directed against the Q-Cells®, as determined by panel reactive antibody (PRA) assay.\n21. Allergy to study treatment (Q-Cells®) or any of its constituents (e.g., chicken eggs), or allergy to any of the co-administered immunosuppressants or any of their excipients.\n22. Subject with any medical condition or using concomitant medication that would contraindicate the use of tacrolimus, mycophenolate mofetil, or prednisone as determined by Investigator.\n23. Subject has undergone stem cell transplantation (including T-cell or bone marrow transplants) at any time prior to study (within or outside the US).\n24. Subject with prior embolus or evidence of deep vein thrombosis (DVT) by venous ultrasound without adequate treatment.\n25. Subject has recent (1 year) or recurrent history of gastrointestinal bleeding or peptic ulcer disease or is under active treatment to prevent recurrence.\n26. Subject with estimated glomerular filtration rate at screening of less than 60 mL\u002Fmin\u002F1.73m2.\n27. Subjects with hereditary deficiency of hypoxanthine-guanine phosphoribosyl-transferase (HGPRT) such as Lesch-Nyhan and Kelley-Seegmiller syndrome.\n28. Vaccination with live virus within 6 weeks of screening.\n29. History or evidence of optic neuritis.\n30. Any reason, in the judgment of the investigator, which would make the subject inappropriate for entry into this trial.","18 Years","70 Years",{"count":57,"type":22},9,"INTERVENTIONAL",[60,61],"PHASE1","PHASE2","This study is a non-randomized, open-label, partially blinded, sequential cohort, dose-escalation study designed to obtain preliminary data on the safety, tolerability, and early activity of Q-Cells® transplantation in subjects with Transverse Myelitis. For each of the dose levels, transplantation of Q-Cells® unilaterally into spinal cord demyelinated lesions will be evaluated. Subjects will be blinded to side of treatment.",[29],[65],"TM","RECRUITING","2026-07-20",{"date":69,"type":38},"2026-07-21",{"date":71,"type":38},"2022-09-20",{"date":73,"type":22},"2028-12",{"name":75,"class":76},"Q Therapeutics, Inc.","INDUSTRY",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":83,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":58,"phases":86,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":46},"100527399","the-impact-of-expressive-emotional-writing-on-facilitating-grief-resolution-in-adults-with-spinal-cord-injury-100527399","NCT06147258","The Impact of Expressive Emotional Writing on Facilitating Grief Resolution in Adults With Spinal Cord Injury","Inclusion Criteria: (1) diagnosis (with evidence) of SCI (traumatic or non-traumatic) with limb weakness; (2) aged \\> 18 years; (3) access to the internet and a computer or to a smartphone that can perform videoconferencing, (4) sufficient English language and cognitive proficiency to complete self-report study questionnaires and understand program content in English, and able to communicate verbally or through writing.\n\n\\-\n\nExclusion Criteria: (1) severe cognitive impairments that prevent online learning and completion of the evaluation; (2) suicidal intent requiring emergency care; (3) consistent psychotherapy within the last 6 months; (4) current or planned participation in psychological therapy or a clinical trial during the study period that could affect the outcomes of the study; or (5) congenital SCI (e.g., spinal bifida)\n\n\\-",true,{"count":85,"type":22},60,[87],"NA","The aim of this study is to evaluate the therapeutic benefits of a 10-week online coach-guided EEWP on psychosocial health among adults with SCI.",[90,29],"Spinal Cord Injuries","2025-12-17",{"date":93,"type":38},"2025-12-24",{"date":95,"type":38},"2024-05-03",{"date":97,"type":22},"2026-12-31",{"name":99,"class":45},"University of Alabama at Birmingham",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":83,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":46},"100417900","aims-writing-for-healing-a-workshop-for-individuals-living-with-paralysis-100417900","NCT04721717","AIM's Writing for Healing: A Workshop for Individuals Living With Paralysis","Inclusion Criteria:\n\n1. Age 18 or older with paralysis living in the community\n2. limb paralysis resulting from a traumatic event\u002Faccident or neurological disease (e.g., spinal cord injury, head injury, stroke, multiple sclerosis, Transverse myelitis, poliomyelitis, peripheral neuropathy, Parkinson's disease, ALS, botulism, and Guillain-Barré syndrome etc) happened after childhood\n3. a non-traumatic spinal cord injury may be caused by arthritis, cancer, inflammation, infections or disk degeneration of the spine\n4. caregivers of people with amyotrophic lateral sclerosis\n5. able to communicate verbally or through writing\n\nExclusion Criteria:\n\n1. known maladaptive behavioral patterns, exhibition of overt psychotic symptoms (e.g., presence of hallucinations, delusions, or thought disorders)\n2. congenital (e.g., spinal bifida, cerebral palsy)",{"count":107,"type":22},160,"The UAB Institute for Arts In Medicine (AIM) is currently implementing an expressive emotional writing pilot project for adults with paralysis caused by neurological conditions such as traumatic head or spinal cord injury.",[90,110,29,111],"Multiple Sclerosis","Amyotrophic Lateral Sclerosis","2025-08-04",{"date":114,"type":38},"2025-08-08",{"date":116,"type":38},"2020-09-01",{"date":118,"type":22},"2027-03-28",{"name":99,"class":45},{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":127,"enrollmentInfo":128,"targetDuration":54,"studyType":23,"phases":4,"briefSummary":130,"conditions":131,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":157},"100440580","swiss-pediatric-inflammatory-brain-disease-registry-swiss-ped-ibraind-100440580","NCT05017142","Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)","Swiss Pediatric Inflammatory Bain Disease Cohort Study","Inclusion Criteria:\n\nAll patients living and\u002For treated in Switzerland with an IBrainD specified in the following list diagnosed from 2005 onward and with a disease onset before the age of 18.\n\n* Written informed consent by patients (and\u002For legal representative(s), if applicable)\n* Optic Neuritis\n* Transverse Myelitis\n* Acute disseminated encephalomyelitis\n* Multiple Sclerosis\n* Neuromyelitis Optica Spectrum Disorders\n* Myelin oligodendrocyte glycoprotein antibody-associated disease\n* Anti-NMDA-R Encephalitis\n* Anti-GAD65 Associated Autoimmune Encephalitis\n* Anti-AMPAR-1\u002F2 Associated Autoimmune Encephalitis\n* Anti-Lgi-1 Associated Autoimmune Encephalitis\n* Anti-CASPR-2 Associated Autoimmune Encephalitis\n* Anti-GABAR-1\u002F2 Associated Autoimmune Encephalitis\n* Onconeuronal Antibody (Hu, Ri, Yo, Amphiphysin, CRMP-5, Ma-1, Ma-2, SOX-1) Associated Autoimmune Encephalitis\n* Hashimoto Encephalopathy\n* CNS Vasculitis\n* CNS Sarcoidosis\n* CNS Lupus\n* Rasmussen Encephalitis\n\nExclusion Criteria:\n\n* Neurological symptoms due to infectious diseases of the CNS\n* Genetic\u002Fmetabolic causes of central demyelinating diseases\n* Neurological symptoms due to Guillain-Barré-Syndrome","36 Years",{"count":129,"type":22},500,"The Swiss-Ped-IBrainD is a national patient registry that collects information on diagnosis, symptoms, treatment, and follow-up of pediatric patients with an inflammatory brain disease in Switzerland. It was first implemented in 2020 in the pediatric clinic of the university hospital in Bern. Further centers all over Switzerland opened for recruitment after that: Aarau, Basel, Bellinzona, Chur, Geneva, Lausanne, Lucerne, St. Gallen, Winterthur and Zurich. The center in Fribourg is expected open for recruitment in 2025. The registry provides data for national and international monitoring and research. It supports research on inflammatory brain diseases in Switzerland and the exchange of knowledge between clinicians, researchers, and therapists. The registry aims to improve the treatment of children with inflammatory brain diseases and optimizing their health care and quality of life.",[132,29,133,110,134,135,136,137,138,139,140,141,142,143,144,145,146,147],"Optic Neuritis","Acute Disseminated Encephalomyelitis","Neuromyelitis Optica Spectrum Disorder","Anti-NMDAR Encephalitis","Anti-GAD65 Associated Autoimmune Encephalitis","Anti-AMPAR-1\u002F2 Associated Autoimmune Encephalitis","Anti-Lgi-1 Associated Autoimmune Encephalitis","Anti-CASPR-2 Associated Autoimmune Encephalitis","Anti-GABAR-1\u002F2 Associated Autoimmune Encephalitis","Onconeuronal Antibody (Hu, Ri, Yo, Amphiphysin, CRMP-5, Ma-1, Ma-2, SOX-1) Associated Autoimmune Encephalitis","Hashimoto Encephalitis","CNS Vasculitis","CNS Sarcoidosis","CNS Lupus","Rasmussen Encephalitis","Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)","2024-12-11",{"date":150,"type":38},"2024-12-16",{"date":152,"type":38},"2020-04-14",{"date":154,"type":22},"2071-01-01",{"name":156,"class":45},"University of Bern",13]